MARKETS / NASDAQ / MGX

NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Metagenomi Therapeutics, Inc. MGX

3 fiscal years on record · USD · FY2025 reported

SEC FILINGS ONLY

Revenue · FY2025

$25.2M

▼ 51.8% vs FY2024

EPS · FY25

$-2.36

Dividend / sh · FY25

—

Payout · FY25

—

ROE · FY25

-44.7%

Net margin · FY25

-348.5%

Dividend coverage

—

Result

USD 25.2M

Revenue, FY2025 · full 3-year series below

Revenue Net income

The company lost 349 cents on every revenue dollar this year.

Per share

USD -2.36

Diluted EPS, FY2025

EPS

The company pays no cash dividend.

Profitability

-44.7%

Return on equity, FY2025

ROE

Operating margin-380.9%

Net margin-348.5%

Return on assets-32.2%

Each USD of equity lost 45 cents this year.

Returned to shareholders

—

returned in FY2025 · dividends + net buybacks

Dividends paid—

Net buybacks—

Share of profit—

Consecutive raises—

Growth

—

revenue, compounded over five years

CAGR

3 yrs

5 yrs

10 yrs

15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base

0.04B

Shares outstanding, FY2025

Change, 5 years—

Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Balance sheet

USD 221.1M

total assets, end of FY2025

Total assetsUSD 221.1M

EquityUSD 158.6M

CashUSD 41.7M

Current ratio7.22×

Equity funds 72% of total assets.

History

3 fiscal years

Every figure from documents filed with the SEC · USD

Metric

2025

2024

2023

Revenue $B

0.0

0.1

0.0

Operating income $B

−0.1

EBITDA $B

−0.1

Income tax $B

−0.0

0.0

Net income $B

−0.1

EPS, diluted $

−2.36

−20.05

Dividend / sh $

Payout %

ROE %

−44.7

−157.3

Shares out B

0.04

0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED

9 of 9

checks passed before publication

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed

Market capitalizationneeds a market quote — not yet licensed

Dividend yieldneeds a market quote — not yet licensed

Price-to-bookneeds a market quote — not yet licensed